Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Registration Number
- NCT00097279
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics compared to the two oral anti-diabetics alone for the control of blood glucose.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 230
Inclusion Criteria
- Subjects with type 2 diabetes mellitus
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HbA1c After 24 weeks
- Secondary Outcome Measures
Name Time Method Safety variables Other glycemic variables 8-point plasma glucose profiles
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of biphasic insulin aspart 70/30 in type 2 diabetes management?
How does NovoLog Mix 70/30 combination therapy compare to metformin and pioglitazone alone in glycemic control?
Which biomarkers correlate with response to biphasic insulin aspart 70/30 in type 2 diabetes patients?
What are the potential adverse events associated with NovoLog Mix 70/30 in combination with metformin and pioglitazone?
How does Novo Nordisk's biphasic insulin aspart 70/30 compare to other basal-bolus insulin regimens in type 2 diabetes treatment?
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇺🇸Milwaukee, Wisconsin, United States
Novo Nordisk Investigational Site🇺🇸Milwaukee, Wisconsin, United States